Legal Opinion
Teva Pharm. USA, Inc. v. Sandoz Inc. (In Re Copaxone Consol. Cases)
Court of Appeals for the Federal Circuit
Decided October 12, 2018No. 2017-1575PublishedCited by 14 opinions
1Opinion of the Court
Reyna, Circuit Judge.
*1016 Plaintiffs-Appellants Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., Teva Neuroscience, Inc., and Yeda Research and Development Co., Ltd., appeal the decision of the United States District Court for the District of Delaware invalidating all asserted claims of patents directed to COPAXONE ® 40mg/mL, a product marketed for treatment of patients with relapsing forms of multiple sclerosis. Because the district court correctly held the asserted claims invalid as obvious under 35 U.S.C. § 103 , we affirm.
BACKGROUND
I. Patents at Issue
Yeda Research &…
2Cases cited19 opinions
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
- Vitronics Corporation v. Conceptronic, Inc.Court of Appeals for the Federal Circuit · 1996
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
14 more not listed; retrieve them via the Exa API.
3Cited by14 opinions
- Allergan Sales, LLC v. Sandoz, Inc.Court of Appeals for the Federal Circuit · 2019
- Omega Patents, LLC v. Calamp Corp.Court of Appeals for the Federal Circuit · 2019
- Yeda Research and Development v. Mylan Pharmaceuticals Inc.Court of Appeals for the Federal Circuit · 2018
- Neptune Generics, LLC v. Eli Lilly & CompanyCourt of Appeals for the Federal Circuit · 2019
- Novartis Pharm. Corp. v. Accord Healthcare Inc.District Court, D. Delaware · 2019
9 more not listed; retrieve them via the Exa API.